AngioDynamics, Inc

AngioDynamics sells to healthcare providers that perform image-guided, minimally invasive procedures, especially in vascular and oncology settings. Its core users include interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses. Buying decisions are driven by clinical outcomes, ease of use, reliability, physician familiarity, and cost-effectiveness, with price pressure increasing as managed care and provider consolidation expand. The company’s products are typically purchased by hospitals, ambulatory and specialty care settings, and physician groups that need disposable or temporarily implanted devices for procedure-based care. Internationally, distributors play a larger role, reflecting local regulatory and commercial requirements.

AngioDynamics is repositioning the business toward its Med Tech portfolio, which management describes as the main engine for future growth. The company is investing in R&D, clinical evidence, and regulatory pathway expansion to support products such as Auryon, mechanical thrombectomy systems, and NanoKnife. It is also streamlining the portfolio through divestitures, product-line discontinuations, and a manufacturing-footprint restructuring that shifts more production to third-party manufacturers. That restructuring is intended to improve gross margin and reduce cost, while preserving a smaller U.S. manufacturing presence for select products and operational functions. Commercially, the company is focused on customer-centric selling, physician training, and international expansion to widen adoption of its higher-technology platforms.